Najafi Ramin Form SC 13G/A February 04, 2011

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2

(Amendment No. 3)*

NOVABAY PHARMACEUTICALS, INC. (Name of Issuer)

(= 111111)

Common Stock (Title of Class of Securities)

66987P102 (CUSIP Number)

December 31, 2010 (Date of Event Which Requires Filing of this Statement)

Check	he appropriate box to designate the rule pursuant to which this Schedule is filed:
[]	Rule 13d-1(b)
[]	Rule 13d-1(c)
[X]	Rule 13d-1(d)

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

^{*} The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of the securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

Page 2 of 8 Pages

1.	Names of Reporting Pers	sons			
2.	Ramin Najafi, Ph.D. Check the Appropriate Box if a Member of a Group (See Instructions)				
	•	X]	•		
2	(b) []			
3.	SEC Use Only				
4.	Citizenship or Place of Organization				
	United States of America	ı			
Number of	5.		Sole Voting Power		
			204,051		
Shares	6.		Shared Voting Power		
Beneficially			3,117,500		
Owned by Each	7.		Sole Dispositive Power		
			204,051		
Reporting	8.		Shared Dispositive Power		
Person With			3,117,500		
9.	Aggregate Amount Bene 3,321,551	ficially Own	ed by Each Reporting Person		
10.		Amount in Ro	ow (9) Excludes Certain Shares (See		
	Instructions)				
11.	Percent of Class Represented by Amount in Row (9) 14.2%*				
12.	Type of Reporting Person (See Instructions) IN				

* Based on 23,391,643 shares of common stock outstanding as of December 31, 2010.

Schedule 13G

CUSIP No. 66987P102

²

Page 3 of 8 Pages

1.	Names of Reporti Farideh Najafi	ing Persons	
2.	·	priate Box if a N	Member of a Group (See Instructions)
	(a)	[X]	(See Instructions)
	(b)	ĺĺ	
3.	SEC Use Only		
4.	Citizenship or Pla	ace of Organiza	tion
	United States of A	America	
Number of	5.		Sole Voting Power
Number of			0
Shares Beneficially	6.		Shared Voting Power
Owned by			3,117,500
Each	7.		Sole Dispositive Power
Reporting			0
Person With	8.		Shared Dispositive Power
Cison With			3,117,500
9.	Aggregate Amou	nt Beneficially	Owned by Each Reporting Person
	3,117,500	•	
10.	Check if the Agg	regate Amount	in Row (9) Excludes Certain Shares (See
	Instructions)		
	[]		
11.	Percent of Class I	Represented by	Amount in Row (9)
	13.3%*		
12.	Type of Reporting	g Person (See II	nstructions)
	IN		

* Based on 23,391,643 shares of common stock outstanding as of December 31, 2010.

Schedule 13G

CUSIP No. 66987P102

³

Page 4 of 8 Pages

Schedule 13G

CUSIP No. 66987P102

1.	Names of Reporting	Persons			
	Najafi Family Trust				
2.	•	Check the Appropriate Box if a Member of a Group (See Instructions)			
	(a)	[X]			
	(b)	[]			
3.	SEC Use Only	. ,			
4.	Citizenship or Place of Organization United States of America				
	5.		Sole Voting Power		
Number of	J.		0		
Shares	6.		Shared Voting Power		
Beneficially	0.		3,117,500		
Owned by	7.		Sole Dispositive Power		
Each	7.		0		
Reporting	8.		Shared Dispositive Power		
Person With	.		3,117,500		
9.	Aggregate Amount E 3,117,500	Beneficially Owner	d by Each Reporting Person		
10.	10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares				
11.	Percent of Class Rep	resented by Amou	int in Row (9)		
	13.3%*	, , , , , , , , , , , , , , , , , , ,			
12.	Type of Reporting Po	erson (See Instruct	tions)		
	00		,		

^{*} Based on 23,391,643 shares of common stock outstanding as of December 31, 2010.

CUSI	IP No.	66987P10	Schedule 13G	Page 5 of 8 Pages
Item 1(a).	Name	of Issuer:		
	NovaE	Bay Pharm	aceuticals, Inc.	
Item 1(b).	Addre	ss of Issue	r's Principal Executive Offices:	
	5980 I	Horton Str	eet, Suite 550, Emeryville, California	94608
	Names	s of Person	s Filing:	
2(a).	Ramin	Najafi, Pl	n.D., Farideh Najafi and the Najafi Fan	nily Trust
Item 2 2(b)	Addres	ss of Princi	pal Business Office or, if None, Reside	ence:
I		•	ceuticals, Inc. et, Suite 550	
			ornia 94608	
	Citizeı	nship:		
		Family Tr	a.D. and Farideh Najafi are citizens of ust is a trust formed under the laws of	
	Title o	of Class of	Securities:	
2(d).	Comm	non Stock		
	CUSII	P Number:		
2(e).	66987	P102		
ItemI 3.	f this s	tatement is	s filed pursuant to §§ 240.13d-1(b) or 2	240.13d-2(b) or (c), check whether the person filing is a:
	(a)		Broker or dealer registered under sec	
	(b)		Bank as defined in section 3(a)(6) of	
	(c) (d)		- ·	ion 3(a)(19) of the Act (15 U.S.C. 78c); section 8 of the Investment Company Act of 1940 (15
	(e)	[]	An investment adviser in accordance	
	(f)			nent fund in accordance with § 240.13d-1(b)(1)(ii)(F);
	(g)			person in accordance with § 240.13d-1(b)(1)(ii)(G);
	(h)) []	A savings association as defined in S U.S.C. 1813);	ection 3(b) of the Federal Deposit Insurance Act (12
	(i)	[]	A church plan that is excluded from t 3(c)(14) of the Investment Company	he definition of an investment company under section Act of 1940 (15 U.S.C. 80a-3);

	(j) (j)	[]	Group, in accordance with § 240.13d-1(b)(1)(ii)(J); A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
	(k)	[]	Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
Not Ap	plicab	le.	

CUSIP No. 66987P102

Schedule 13G

Page 6 of 8 Pages

Item 4. Ownership.

As of December 31, 2010:

(a) Amount Beneficially Owned:

 Ramin Najafi, Ph.D.
 3,

 321,551
 3,117,500

 Najafi Family Trust
 3,117,500

(b) Percent of Class:

Ramin Najafi, Ph.D. 14.2% Farideh Najafi 13.3% Najafi Family Trust 13.3%

- (c) Number of shares as to which such person has:
- (i) Sole power to vote or to direct the vote:

Ramin Najafi, Ph.D. 204,051
Farideh Najafi 0
Najafi Family Trust 0

(ii) Shared power to vote or to direct the vote:

Ramin Najafi, Ph.D.3,117,500Farideh Najafi3,117,500Najafi Family Trust3,117,500

(iii) Sole power to dispose or to direct the disposition of:

Ramin Najafi, Ph.D. 204,051
Farideh Najafi 0
Najafi Family Trust 0

(iv) Shared power to dispose or to direct the disposition of:

Ramin Najafi, Ph.D 3,117,500 Farideh Najafi 3,117,500 Najafi Family Trust 3,117,500

The 3,321,551 shares beneficially owned by Ramin Najafi, Ph.D. includes 3,117,500 shares held by the Najafi Family Trust; 11,200 shares held by Ramin Najafi and 192,851 option shares that can be exercised within 60 days from December 31, 2010. The shares beneficially owned by Farideh Najafi and the Najafi Family Trust consist solely of 3,117,500 shares held by the Najafi Family Trust. Dr. and Mrs. Najafi are co-trustees of the Najafi Family Trust.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. []

CUSIP No. 66987P102

Schedule 13G

Page 7 of 8 Pages

ItemOwnership of More than Five Percent on Behalf of Another Person.

6.

Not applicable.

ItemIdentification and Classification of the Subsidiary Which Acquired the Security

7. Being Reported on by the Parent Holding Company or Control Person.

Not applicable.

ItemIdentification and Classification of Members of the Group.

8.

This filing is on behalf of Ramin Najafi, Ph.D., Farideh Najafi and the Najafi Family Trust as members of a group pursuant to Rule 13d-1(d).

ItemNotice of Dissolution of Group.

9

Not applicable.

ItemCertifications.

10.

Not applicable.

CUSIP No. 66987P102

Schedule 13G

Page 8 of 8 Pages

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

February 4, 2011 (Date)

/s/ Ramin Najafi Ramin Najafi, Ph.D.

/s/ Farideh najafi Farideh Najafi

NAJAFI FAMILY TRUST

/s/ Ramin Najafi

By: Ramin Najafi, Ph.D.

Co-Trustee

/s/ Faridef najafi By: Farideh Najafi

Co-Trustee

EXHIBIT A

Joint Filing Agreement

This Joint Filing Agreement is dated as of February 4, 2011 by and among Ramin Najafi, Ph.D., Farideh Najafi and the Najafi Family Trust.

WHEREAS, pursuant to Rule 240.13d-1(k) promulgated under Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), the parties hereto have decided to satisfy their filing obligations under the Exchange Act by a single joint filing;

NOW THEREFORE, the parties hereto agree as follows:

- 1. The Schedule 13G with respect to NovaBay Pharmaceuticals, Inc. to which this agreement is attached as Exhibit A (the "Schedule 13G") is filed on behalf of each of the parties hereto.
- 2. Each of the parties hereto is eligible to use the Schedule 13G.
- 3. Each of the parties hereto is responsible for the timely filing of the Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such person or entity contained in the Schedule 13G; provided that each person or entity is not responsible for the completeness or accuracy of the information concerning any other person making such filing contained in the Schedule 13G, unless such person or entity knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the parties hereto have executed this Joint Filing Agreement as of the date first above written.

/s/ Ramin Najafi Ramin Najafi, Ph.D.

/s/ Farideh najafi Farideh Najafi

NAJAFI FAMILY TRUST

/s/ Ramin Najafi By: Ramin Najafi, Ph.D. Co-Trustee

/s/ Faridef najafi By: Farideh Najafi Co-Trustee